Clinical Trials Logo

Healthy Adults clinical trials

View clinical trials related to Healthy Adults.

Filter by:

NCT ID: NCT05317507 Recruiting - Healthy Adults Clinical Trials

Safety of Co-Administered CHI-554 and Alcohol

Start date: May 9, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, randomized, double-blind study to assess the safety, tolerability, and effects of CHI-554 when co-administered with alcohol.

NCT ID: NCT05188079 Recruiting - Healthy Adults Clinical Trials

Effect of Acute Nitrate Supplementation on Vascular Function in Hispanic, Black and White Population

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to assess vascular function in African Americans, Hispanic and Caucasian Americans to better understand racial differences in cardiovascular health. The investigators will further investigate the affect of Beetroot juice on the vascular function of all participants.

NCT ID: NCT04842682 Recruiting - Healthy Adults Clinical Trials

Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers

Start date: March 29, 2021
Phase: Phase 1
Study type: Interventional

Multicenter double-blind placebo controlled phase I dose-escalation trial that will be conducted in France and Switzerland to evaluate different dose levels of CD40.HIVRI.Env (adjuvanted with Hiltonol) alone and in co-administration with DNA-HIV-PT123. A total of 72 eligible healthy participants will be recruited into 6 groups. Within each group, participants will be randomized in a double blind manner to active intervention or placebo in a 5:1 ratio. Enrolment into a given group (other than group "Solo 0.3") will open sequentially depending on the " go-criterion " based on the safety data of the preceding group(s). The primary objective is to assess the safety of three dose levels of CD40.HIVRI.Env (0.3; 1; 3 mg) adjuvanted with Poly-ICLC (Hiltonol®), alone and in combination with DNA-HIV-PT123, administered at weeks 0, 4 and 24 in healthy participants. Secondary objectives are to assess the capacity of poly-ICLC-adjuvanted CD40.HIVRI.Env alone and in combination with DNA-HIV-PT123 to elicit immune responses against HIV (immunogenicity): - Humoral (antibody) responses ; - B-cell responses ; - T-cell responses.

NCT ID: NCT04104360 Recruiting - Healthy Adults Clinical Trials

Galacto-oligosaccharides and Intestinal Activity

Start date: September 17, 2019
Phase: N/A
Study type: Interventional

Dietary intake of galacto-oligosaccharides (GOS) may have beneficial effects on host health by affecting the microbiota composition and -activity. So far studies focused on analyses in fecal samples, while the primary site of carbohydrate fermentation is the proximal colon. To date, no studies have been performed in humans on the more proximal microbiota and the impact of fermentable carbohydrates. Further insights on the more proximal colonic microbiota would aid to targeted approaches to improve intestinal health. Therefore, we aim to study the effect of GOS on the intestinal microbiota composition and -activity in healthy adults, by sampling the more proximal human colon in a physiological condition. The primary objective of this study is to investigate the impact of four weeks GOS supplementation on intestinal microbiota composition and -activity, by sampling the proximal part of the human colon in a physiological condition. Furthermore, this study has four secondary objectives: First, to compare the intestinal microbiota composition and -activity of the proximal colon vs. distal colon at baseline and after four weeks GOS supplementation. Second, compare the luminal microbiota composition vs. mucosa adherent microbiota composition of the proximal vs. distal colon at baseline and after four weeks GOS supplementation. Third, monitor the effects of four weeks GOS supplementation on gastrointestinal symptoms. The study conforms to a randomized, double-blind, placebo-controlled, parallel design. Study population includes healthy human volunteers (male and female), 18-50 years of age. One intervention arm will include 7.2 grams of Vivinal® GOS Powder three times daily for four weeks. The other intervention arm subjects will receive placebo product (7.2 grams maltodextrin) three times daily for four weeks. At the start and end of the intervention period, several measurements will take place. The main study parameter is the change in microbial composition and -activity induced by GOS intervention.

NCT ID: NCT03733613 Recruiting - Healthy Adults Clinical Trials

Reliability and Validity of Kinect Detector for Fitness Tests and Gait Performance Analysis

Start date: November 1, 2018
Phase:
Study type: Observational

Background: Depending on nature and needs, physical fitness can be divided into healthy fitness and physical fitness (also known as competitive fitness). Healthy fitness includes cardio-respiratory fitness, muscle fitness, muscular endurance, flexibility, and body composition. Physical fitness includes coordination, speed, explosiveness, balance, agility, and reaction time. Although the monitoring of fitness is very important, most of the tests need to be assisted by professionally trained fitness inspectors, so that the public who wants to regularly check their fitness status will facing a dilemma-- insufficient of inspectors. In the face of such a situation, the somatosensory detector may be a choice which is relatively objective, convenient and no need to rely on the inspectors. Therefore, the validity and retest reliability of the somatosensory detector need to be verified in order to achieve accurate and objective measurement results.

NCT ID: NCT03427853 Recruiting - Healthy Adults Clinical Trials

A Study to Evaluate the Denosumab in Healthy Adults

Start date: January 10, 2018
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, parallel-group, placebo-controlled, single-dose escalation Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of denosumab injection administered subcutaneously to healthy adults in China

NCT ID: NCT01703377 Recruiting - Healthy Adults Clinical Trials

Effect of Constraining Joint Motions on Postural Control

Start date: April 2012
Phase: N/A
Study type: Observational

A major advantage of understanding a neural control scheme is able to simultaneously perform multiple tasks based on the Uncontrolled Manifold (UCM) hypothesis by taking advantage of motor redundancy. The present study aims to investigate this hypothesis further by examining the effect of artificially eliminating knee and lumbar-thoracic joint motions on postural control when the arms performing targeting task simultaneously in standing. Subjects (Younger group: 20~35 years old; Elder group: 60~85 years old) will execute a targeting task with and without an additional ball-balancing task in standing with free joint motions and with restricted joint motions. The investigators expect to recruit 50 subjects for each group. Analyses of joint configuration variance on the stability of the center of mass (COM) position and the hand path will be performed using the UCM method of variance analysis. This method partitions joint configuration variance into one component consistent with the use of motor abundance and a component that leads to COM position or hand path variability. Furthermore, the differences between the younger group and the elder group will be evaluated.